公开(公告)号：US11957757B2

公开(公告)日：2024-04-16

申请号：US17328282

申请日：2021-05-24

申请人： AUBURN UNIVERSITY

发明人： Feng Li ,  Wu Chen ,  Pengyu Chen

IPC分类号： A61K47/52 ,  A61K31/325 ,  A61K31/337 ,  A61K31/704 ,  A61K33/24 ,  A61K33/242 ,  A61K33/243 ,  A61K33/244 ,  A61K47/69 ,  A61K49/18 ,  C07F1/08

CPC分类号： A61K47/52 ,  A61K31/325 ,  A61K31/337 ,  A61K31/704 ,  A61K33/24 ,  A61K33/242 ,  A61K33/243 ,  A61K33/244 ,  A61K47/6923 ,  A61K49/1824 ,  C07F1/08

摘要： The present disclosure provides method of making a nanoparticle complex wherein the nanoparticle complex comprises a ligand and a metal cation. The disclosure also provides nanoparticle complexes, methods of treating a disease in a patient utilizing the nanoparticle complexes, methods of identifying a disease in a patient utilizing the nanoparticle complexes, and kits involving the nanoparticle complexes.

公开(公告)号：US11878064B2

公开(公告)日：2024-01-23

申请号：US18170229

申请日：2023-02-16

申请人： US Department of the Navy

发明人： James B. Delehanty ,  Megan Muroski ,  Eunkeu Oh ,  Jeffrey R. Deschamps

IPC分类号： A61K47/69 ,  A61K38/17 ,  A61K47/52

CPC分类号： A61K47/6929 ,  A61K38/17 ,  A61K47/52

摘要： A nanoparticle (NP)-peptide conjugate provides efficient steric hindrance/blockage of cellular membrane potassium (K+) channels to mediate depolarization of cellular membrane potential.

公开(公告)号：US20230241222A1

公开(公告)日：2023-08-03

申请号：US18009725

申请日：2020-06-22

申请人： Ahmed Abdelaal AHMED MAHMOUD METWALLY ALKHATIP

发明人： Ahmed Abdelaal AHMED MAHMOUD METWALLY ALKHATIP

IPC分类号： A61K47/52

CPC分类号： A61K47/52

摘要： The present invention provides a pharmaceutical composition comprising a compound for use in preventing and/or treating infections caused by SARS-CoV2. There is also provided, the use of a pharmaceutical composition comprising a compound for the manufacture of a medicament for the prevention and/or the treatment of infections caused by SARS-CoV-2. Besides that, the present disclosure relates also to a method for inhibiting the production of SARS-CoV2. Provided, a method for virtual screening for such compounds.

公开(公告)号：US20230234850A1

公开(公告)日：2023-07-27

申请号：US18172695

申请日：2023-02-22

申请人： Merck Sharp & Dohme LLC

发明人： Akhilesh Bhambhani ,  Muneeswara Babu Medi ,  Maya Salnikova ,  William James Smith ,  David S. Thiriot

IPC分类号： C01B25/36 ,  A61K47/52 ,  A61K39/39

CPC分类号： C01B25/36 ,  A61K47/52 ,  A61K39/39 ,  A61K2039/55505

摘要： Vaccine formulations are described comprising physically separated, lyophilized antigens and adjuvant components, which may be in lyoparticle form, as well as methods of using and making such formulations. Reconstituted formulations are also described.

公开(公告)号：US20230210996A1

公开(公告)日：2023-07-06

申请号：US17834314

申请日：2022-06-07

申请人： Korea University Research and Business Foundation

发明人： Young-Keun KIM ,  Heemin KANG ,  THOMAS MYEONGSEOK KOO ,  Myeong-Soo KIM ,  Yuri KIM

IPC分类号： A61K47/52 ,  A61K47/69

CPC分类号： A61K47/52 ,  A61K47/6929 ,  B82Y5/00

摘要： According to the present invention, it is possible to provide a nanosatellite-substrate complex capable of regulating macrophage adhesion and polarization. In addition, according to the present invention, it is possible to provide a method for preparing a nanosatellite-substrate complex capable of regulating macrophage adhesion and polarization. In addition, according to the present invention, it is possible to provide a method of regulating macrophage adhesion and polarization using the nanosatellite-substrate complex.

公开(公告)号：US11690833B2

公开(公告)日：2023-07-04

申请号：US16955160

申请日：2018-12-07

申请人： Colgate-Palmolive Company

发明人： Viktor Dubovoy ,  Junhong Mao ,  Ravi Subramanyam ,  Long Pan ,  Tatiana Brinzari

IPC分类号： A61K31/4425 ,  A61K47/52

CPC分类号： A61K31/4425 ,  A61K47/52

摘要： Described herein are complexes comprising a cationic antibacterial agent and a metal salt, personal care compositions comprising same; along with methods of making and using these complexes and compositions.

公开(公告)号：US20190202884A1

公开(公告)日：2019-07-04

申请号：US16278851

申请日：2019-02-19

申请人： Purdue Research Foundation

发明人： Elizabeth M. Murphy Topp ,  Hamed Tabatabaei Ghomi ,  Markus Lill ,  Shenbaga Moorthy Balakrishnan

IPC分类号： C07K14/605

CPC分类号： C07K14/605 ,  A61K38/00 ,  A61K38/26 ,  A61K47/52

摘要： The invention generally relates to modified glucagon molecules. In certain embodiments, the invention provides a glucagon molecule that includes one or more modified amino acids to result in the glucagon molecule being soluble at a substantially neutral pH and resistant to fibrillation.

公开(公告)号：US10080811B2

公开(公告)日：2018-09-25

申请号：US14382728

申请日：2013-03-07

申请人： University of Leeds

发明人： Sikha Saha ,  Gin Jose ,  Animesh Jha

IPC分类号： A61B5/1455 ,  A61K49/00 ,  A61B5/00 ,  A61K47/52

CPC分类号： A61K49/0019 ,  A61B5/0059 ,  A61B5/0071 ,  A61B5/0075 ,  A61B5/0077 ,  A61B5/14546 ,  A61B5/1455 ,  A61B2560/0223 ,  A61K47/52 ,  A61K49/0004

摘要： The present Invention relates to the monitoring of biological substances, such as non-invasive monitoring of such substances in animal, for examples biomarkers and metabolites. Specifically, the invention further relates to such monitoring using rare earth tagged marker compounds. The invention further relates to such monitoring using laser spectroscopy or Raman spectroscopy. The invention further relates to the use of such monitoring in disease states, such as stroke, neurological disorders and cardiovascular disorders. The invention further relates to novel rare-earth conjugated marker compounds and processes for preparing said rare-earth conjugated compounds

公开(公告)号：US20180264035A1

公开(公告)日：2018-09-20

申请号：US15984035

申请日：2018-05-18

申请人： Erica D. Bruce ,  John W. Woodmansee, JR.

发明人： Erica D. Bruce ,  John W. Woodmansee, JR.

IPC分类号： A61K33/08 ,  A61K33/06 ,  A61K47/69 ,  A61K47/02 ,  A61K9/08 ,  A61K9/00

CPC分类号： A61K33/08 ,  A61K9/0026 ,  A61K9/08 ,  A61K33/06 ,  A61K47/02 ,  A61K47/52 ,  A61K47/6921 ,  A61K47/6923

摘要： A method of treating a mammal, comprising administering a therapeutically effective amount of a poly-oxygenated metal hydroxide composition to a mammal to reduce a proliferation of hypoxic carcinoma cells, wherein the poly-oxygenated metal hydroxide composition comprises a clathrate containing free oxygen gas (O2) molecules. The carcinoma cells may comprise colon adenocarcinoma cells (CaCo-2). The poly-oxygenated metal hydroxide material is configured to provide bioavailable oxygen gas molecules to a mammal when administered to the mammal. The poly-oxygenated metal hydroxide composition can be administered intravenously, directly to carcinoma cells, and orally. The composition may comprise a fluid, where the poly-oxygenated metal hydroxide composition is soluble in the fluid.

公开(公告)号：US20180264034A1

公开(公告)日：2018-09-20

申请号：US15983922

申请日：2018-05-18

申请人： Erica D. Bruce ,  John W. Woodmansee, JR.

发明人： Erica D. Bruce ,  John W. Woodmansee, JR.

IPC分类号： A61K33/08 ,  A61K33/06 ,  A61K47/69 ,  A61K9/00 ,  A61K47/02 ,  A61K9/08

CPC分类号： A61K33/08 ,  A61K9/0026 ,  A61K9/08 ,  A61K33/06 ,  A61K47/02 ,  A61K47/52 ,  A61K47/6921 ,  A61K47/6923 ,  A61K47/6949

摘要： A method of treating a mammal, comprising administering a therapeutically effective amount of a poly-oxygenated metal hydroxide composition to a mammal to reduce a proliferation of hypoxic carcinoma cells, wherein the poly-oxygenated metal hydroxide composition comprises a clathrate containing free oxygen gas (O2) molecules. The carcinoma cells may comprise prostrate carcinoma (22Rv1). The poly-oxygenated metal hydroxide material is configured to provide bioavailable oxygen gas molecules to a mammal when administered to the mammal. The poly-oxygenated metal hydroxide composition can be administered intravenously, directly to carcinoma cells, and orally. The composition may comprise a fluid, where the poly-oxygenated metal hydroxide composition is soluble in the fluid.